- Home
- AQB vs CHEK Comparison
AQB vs CHEK Comparison
Compare AQB & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQB
- CHEK
- Stock Information
- Founded
- AQB 1991
- CHEK 2004
- Country
- AQB United States
- CHEK Israel
- Employees
- AQB N/A
- CHEK N/A
- Industry
- AQB
- CHEK Medical Electronics
- Sector
- AQB
- CHEK Health Care
- Exchange
- AQB Nasdaq
- CHEK Nasdaq
- Market Cap
- AQB 4.0M
- CHEK 3.9M
- IPO Year
- AQB N/A
- CHEK 2015
- Fundamental
- Price
- AQB $1.07
- CHEK $1.99
- Analyst Decision
- AQB
- CHEK
- Analyst Count
- AQB 0
- CHEK 0
- Target Price
- AQB N/A
- CHEK N/A
- AVG Volume (30 Days)
- AQB 55.8K
- CHEK 97.7K
- Earning Date
- AQB 10-28-2025
- CHEK 11-28-2025
- Dividend Yield
- AQB N/A
- CHEK N/A
- EPS Growth
- AQB N/A
- CHEK N/A
- EPS
- AQB N/A
- CHEK N/A
- Revenue
- AQB N/A
- CHEK N/A
- Revenue This Year
- AQB N/A
- CHEK N/A
- Revenue Next Year
- AQB N/A
- CHEK N/A
- P/E Ratio
- AQB N/A
- CHEK N/A
- Revenue Growth
- AQB N/A
- CHEK N/A
- 52 Week Low
- AQB $0.47
- CHEK $0.56
- 52 Week High
- AQB $2.95
- CHEK $3.13
- Technical
- Relative Strength Index (RSI)
- AQB 36.52
- CHEK 60.03
- Support Level
- AQB $0.98
- CHEK $1.55
- Resistance Level
- AQB $1.13
- CHEK $1.90
- Average True Range (ATR)
- AQB 0.09
- CHEK 0.16
- MACD
- AQB -0.02
- CHEK 0.05
- Stochastic Oscillator
- AQB 16.60
- CHEK 92.31
About AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.